Literature DB >> 15225267

Capillary blood cell velocity in periulcerous regions of the lower leg measured by laser Doppler anemometry.

Markus Stücker1, Christina Huntermann, Falk Georges Bechara, Klaus Hoffmann, Peter Altmeyer.   

Abstract

BACKGROUND: The capillary blood flow of the nailfold can be measured by means of modern non-invasive techniques like the videocapillary microscope in vivo. To quantify the capillary blood cell velocity, apart from the nailfold capillaries, we used a new technique, the so-called laser Doppler anemometry (LDA).
OBJECTIVE: The present study investigated how far laser Doppler fluxmetry (LDF), transcutaneous partial pressure of oxygen (tcpO2), and LDA are capable of quantifying differences of cutaneous microcirculation between patients with leg ulcera and a healthy control group. The effects of intravenous prostaglandin E1 and pentoxifylline were also investigated. PATIENTS AND METHODS: Ten patients with venous leg ulcers and 10 patients with mixed venous/arterial ulcers were investigated with LDF, tcpO2, and LDA before and after injection of prostaglandin E1 and pentoxifylline. We measured the resting capillary blood cell velocity (rCBV), the maximum hyperemia, and the time to peak capillary blood cell velocity (tpCBV) during hyperemia after 4 min of suprasystolic occlusion and compared them with the results of a contol group of 20 patients.
RESULTS: Laser Doppler flow was increased in all patients during resting period, whereas the tcpO2 was significantly decreased. LDF did not show an extension of tpCBV during reactive hyperemia after suprasystolic occlusion compared to the control group (73.6+/-31.1 vs. 164.1+/-52.5 s, P=0.003). TcpO2 revealed significantly decreased tpCBV in patients with venous and mixed venous/arterial ulcers (90.1+/-61.7 vs. 162.7+/-65.5 s, P< or =0.0001). LDA showed no significant differences between patients and control group (P>0.8). After application of prostaglandin E1, LDA revealed a significant increase of erythrocyte velocity (0.5+/-0.18 to 0.74+/-0.28 mm/s [P=0,01]), whereas pentoxifylline had no significant effect. Capillary density increased significantly after application of prostaglandin E1 (5,1+/-2.7/mm2 to 8.9+/-3/mm2 [P=0.001]) and pentoxifylline (5.3+/- 1.8/mm2 to 8+/-2.1/mm2 [P=0.006]).
CONCLUSION: The LDA is an important additional investigation tool for cutaneous microcirculation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225267     DOI: 10.1111/j.1600-0846.2004.00064.x

Source DB:  PubMed          Journal:  Skin Res Technol        ISSN: 0909-752X            Impact factor:   2.365


  5 in total

Review 1.  [Vacuum-therapy of chronic wounds in dermatologic departments].

Authors:  J Dissemond
Journal:  Hautarzt       Date:  2008-08       Impact factor: 0.751

2.  Tissue Oxygenation Changes to Assess Healing in Venous Leg Ulcers Using Near-Infrared Optical Imaging.

Authors:  Rebecca Kwasinski; Cristianne Fernandez; Kevin Leiva; Richard Schutzman; Edwin Robledo; Penelope Kallis; Luis J Borda; Robert Kirsner; Francisco Perez-Clavijo; Anuradha Godavarty
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-10-16       Impact factor: 4.730

3.  Coherent flow power Doppler (CFPD): flow detection using spatial coherence beamforming.

Authors:  You Leo Li; Jeremy J Dahl
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2015-06       Impact factor: 2.725

4.  Assessment of intravoxel incoherent motion MRI with an artificial capillary network: analysis of biexponential and phase-distribution models.

Authors:  Moritz Jörg Schneider; Thomas Gaass; Jens Ricke; Julien Dinkel; Olaf Dietrich
Journal:  Magn Reson Med       Date:  2019-05-26       Impact factor: 4.668

5.  Very different performance of the power Doppler modalities of several ultrasound machines ascertained by a microvessel flow phantom.

Authors:  David F Ten Cate; Jolanda J Luime; Myrthe van der Ven; Johanna M W Hazes; Klazina Kooiman; Nico de Jong; Johannes G Bosch
Journal:  Arthritis Res Ther       Date:  2013-10-24       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.